Fagoterapia develops personalized bacteriophage therapies to combat antibiotic-resistant bacterial infections. Their five-step process delivers targeted treatments within 7-10 days, offering a precise alternative to conventional antibiotics for complex and difficult-to-treat infections.
Funding
Funding not disclosed
Founders
Product
Problem
The increasing prevalence of antibiotic-resistant bacteria renders conventional treatments ineffective, posing a significant global health challenge. This necessitates the development of alternative therapeutic strategies to combat difficult-to-treat bacterial infections.
Solution
Fagoterapia develops bacteriophage-based therapies as a precise and effective alternative to conventional antibiotics. Their approach leverages bacteriophages, naturally occurring viruses that specifically target and destroy harmful bacteria without impacting beneficial microbiota. The company offers a comprehensive, five-step process from bacterial sampling to formulation production, enabling personalized treatments within 7 to 10 days. This technology aims to address the growing crisis of antimicrobial resistance by providing targeted solutions for infections that are resistant or difficult to treat with existing antibiotics.
Target Audience
The primary target audience includes healthcare providers, hospitals, and research institutions seeking advanced therapeutic options for patients with antibiotic-resistant or complex bacterial infections.
Features
- Development of bacteriophage-based therapeutics for antibiotic-resistant bacterial infections.
- Proprietary bioinformatics tools and algorithms for phage host prediction and engineering.
- Phage biobanking with hundreds of characterized bacteriophage isolates active against critical bacteria.
- Functional characterization services for phage isolates.
- Clinical support and consultancy for the application of phage therapy in patient care.
- Case report publication demonstrating successful customized phage therapy for a hip prosthesis infection.
- Participation in European research projects, such as IPCEI "Med4Cure," to advance phage therapy development.